CGON Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $42,664,288.80

CG Oncology Insider Trading History Chart

This chart shows the insider buying and selling history at CG Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$30ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

CG Oncology Share Price & Price History

Current Price: $27.18
Price Change: Price Increase of +0.346 (1.29%)
As of 03/6/2025 01:10 PM ET

This chart shows the closing price history over time for CGON up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$26.83Closing price on 03/05/25:

SEC Filings (Institutional Ownership Changes) for CG Oncology (NASDAQ:CGON)

26.56% of CG Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CGON by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$352Mbought$42MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
CG Oncology logo
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
Read More on CG Oncology

Today's Range

Now: $27.18
Low: $26.00
High: $28.08

50 Day Range

MA: $28.72
Low: $24.64
High: $31.01

52 Week Range

Now: $27.18
Low: $23.91
High: $46.99

Volume

384,648 shs

Average Volume

570,001 shs

Market Capitalization

$2.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Who are the company insiders with the largest holdings of CG Oncology?

CG Oncology's top insider investors include:
  1. Hong Fang Song (Director)
  2. Decheng Capital Global Life Sc (Major Shareholder)
  3. Corleen M Roche (CFO)
  4. Vijay Kasturi (Insider)
  5. Leonard E Post (Director)
Learn More about top insider investors at CG Oncology.

Who are the major institutional investors of CG Oncology?

CG Oncology's top institutional shareholders include:
  1. Decheng Capital LLC — 8.38%
  2. Vanguard Group Inc. — 7.71%
  3. Braidwell LP — 4.32%
  4. Foresite Capital Management VI LLC — 2.92%
  5. Wellington Management Group LLP — 2.51%
  6. Alliancebernstein L.P. — 2.39%
Learn More about top institutional investors of CG Oncology stock.

Which institutional investors are selling CG Oncology stock?

During the last quarter, CGON stock was sold by these institutional investors:
  1. Avidity Partners Management LP
  2. Point72 Asset Management L.P.
  3. Adage Capital Partners GP L.L.C.
  4. Ally Bridge Group NY LLC
  5. CenterBook Partners LP
  6. Corebridge Financial Inc.
  7. Nuveen Asset Management LLC
  8. Janus Henderson Group PLC
During the last year, company insiders that have sold CG Oncology company stock include:
  1. Hong Fang Song (Director)
  2. Decheng Capital Global Life Sc (Major Shareholder)
Learn More investors selling CG Oncology stock.

Which institutional investors are buying CG Oncology stock?

In the last quarter, CGON stock was bought by institutional investors including:
  1. Foresite Capital Management VI LLC
  2. Marshall Wace LLP
  3. Wellington Management Group LLP
  4. Acorn Capital Advisors LLC
  5. Decheng Capital LLC
  6. Vanguard Group Inc.
  7. Orbimed Advisors LLC
  8. Alliancebernstein L.P.
During the previous year, these company insiders have bought CG Oncology stock:
  1. Hong Fang Song (Director)
  2. Decheng Capital Global Life Sc (Major Shareholder)
  3. Corleen M Roche (CFO)
  4. Vijay Kasturi (Insider)
Learn More investors buying CG Oncology stock.